Yestar Healthcare Holdings Company Limited
巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the "Board") of directors (the "Directors") of Yestar Healthcare Holdings Company Limited (the "Company") is pleased to announce that Mr. Li Bin ("Mr. Li") has been appointed as an executive Director of the Company with effect from 18 June 2021. The biographical details of Mr. Li is set out below:

Mr. Li, aged 48, joined the Group in August 2015 as the chief executive officer of a non-wholly owned subsidiary of the Company. Mr. Li is the founder of Shanghai Emphasis Investment Management Consulting Co., Ltd. ("Shanghai Anbaida"), a company incorporated in the People's Republic of China in 2005 and became a non-wholly owned subsidiary of the Company upon completion of the acquisition of its 70% equity interests by the Company in 2015. Mr. Li is primarily responsible for the development of the overall strategy and the formation of strategic goals of Shanghai Anbaida, as well as the supervision and management of Shanghai Anbaida's sales. As at the date of this announcement, Mr. Li holds approximately 9.69% of issued shares of Shanghai Anbaida.

Mr. Li has over 20 years of experience in the sale and distribution of medical equipment and consumables. He was a committee member of 上海市青年聯合會 (Shanghai Youth Federation) in 2003.

Mr. Li has entered into a service agreement with the Company for an initial term of three years with effect from 18 June 2021, subject to normal retirement and re-election by shareholders of the Company pursuant to the articles and association of the Company. Mr. Li is entitled to an annual salary of approximately RMB2,500,000, which was determined with reference to his duties and responsibilities, the Company's remuneration policy, the prevailing market conditions and recommendations of the remuneration committee of the Board. Mr. Li's remuneration will be subject to annual review by the remuneration committee of the Board and the Board from time to time with reference to his responsibility and performance.

Mr. Li shall hold office until the next general meeting of the Company and will be eligible for and subject to re-election at such meeting in accordance with the articles of association of the Company.

Save as disclosed above, Mr. Li does not hold any other positions in the Company or its subsidiaries nor any directorship in other listed public company in the last three years.

Mr. Li does not have any relationship with any Directors, senior management, substantial or controlling Shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules")) of the Company.

As at the date of this announcement, Mr. Li is beneficially interested in 164,600,600 Shares, representing approximately 7.00% of the total issued Shares of the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)) (the "SFO") of the Company.

Save as disclosed above, to the best of the knowledge, information and belief of the Directors after having made all reasonable enquiries, there was no matter relating to the appointment of Mr. Li as an executive Director that needs to be brought to the attention of the Shareholders and there is no other information which is required to be disclosed pursuant to any requirements of Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would also like to express its warmest welcome to Mr. Li on his appointment.

By Order of the Board
Yestar Healthcare Holdings Company Limited
Hartono James
Chairman, CEO and Executive Director

18 June 2021

As at the date of this announcement, the executive Directors are Mr. Hartono James, Ms. Wang Ying, Ms. Wang Hong, Ms. Liao Changxiang and Mr. Li Bin; the independent non-executive Directors are Dr. Hu Yiming, Mr. Zeng Jinsong and Mr. Sutikno Liky.